Grünenthal, a leading global pharmaceutical company specializing in pain management and related diseases, has entered into a strategic licensing agreement with Apotex Inc., the largest Canadian-based pharmaceutical company. The agreement grants Apotex exclusive rights to market and distribute Qutenza®, a topical pain patch for the management of neuropathic pain, in Canada. Under the terms of the…
No responses yet